We developed and validated a clinically useful nomogram including UGT1A1 genotype and other non-genetic factors for predicting the risk of severe neutropenia in the first cycle of irinotecan-based chemotherapy. The gene discussed is UGT1A1; the disease is Decreased total neutrophil count.